Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Galectin Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Galectin Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Galectin Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Galectin Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Galectin Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Galectin Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Galectin Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Galectin Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Galectin Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Galectin Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Galectin Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galectin Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Galectin Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Galectin Therapeutics, Inc. Snapshot 5 Galectin Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Galectin Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Galectin Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Galectin Therapeutics, Inc. - Pipeline Products Glance 11 Galectin Therapeutics, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Galectin Therapeutics, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Galectin Therapeutics, Inc. - Drug Profiles 14 GR-MD-02 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 GM-CT-01 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 GM-CT-02 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 GR-MD-01 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 GR-MD-03 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 GR-MD-04 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Polysaccharides to Inhibit Galectin for Fibrosis, Inflammation and Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Galectin Therapeutics, Inc. - Pipeline Analysis 24 Galectin Therapeutics, Inc. - Pipeline Products by Target 24 Galectin Therapeutics, Inc. - Pipeline Products by Route of Administration 25 Galectin Therapeutics, Inc. - Pipeline Products by Molecule Type 26 Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action 27 Galectin Therapeutics, Inc. - Recent Pipeline Updates 28 Galectin Therapeutics, Inc. - Dormant Projects 36 Galectin Therapeutics, Inc. - Discontinued Pipeline Products 37 Discontinued Pipeline Product Profiles 37 GM-CT-01 37 Galectin Therapeutics, Inc. - Locations And Subsidiaries 38 Head Office 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables Galectin Therapeutics, Inc., Key Information 5 Galectin Therapeutics, Inc., Key Facts 5 Galectin Therapeutics, Inc. - Pipeline by Indication, 2014 8 Galectin Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Galectin Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Galectin Therapeutics, Inc. - Phase I, 2014 11 Galectin Therapeutics, Inc. - Preclinical, 2014 12 Galectin Therapeutics, Inc. - Discovery, 2014 13 Galectin Therapeutics, Inc. - Pipeline by Target, 2014 24 Galectin Therapeutics, Inc. - Pipeline by Route of Administration, 2014 25 Galectin Therapeutics, Inc. - Pipeline by Molecule Type, 2014 26 Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 27 Galectin Therapeutics, Inc. - Recent Pipeline Updates, 2014 28 Galectin Therapeutics, Inc. - Dormant Developmental Projects,2014 36 Galectin Therapeutics, Inc. - Discontinued Pipeline Products, 2014 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.